Cardiac Troponin and its Relationship to Cardiovascular Outcomes in Community Populations - A Systematic Review and Meta-analysis

Heart Lung and Circulation

Volumn 25, Issue 3, 2016, Pages 217-228

  Sze, Julie ^a,b   Mooney, John ^a,d   Barzi, Federica ^a   Hillis, Graham S ^a,c   Chow, Clara K ^a,b,d  

^a GEORGE INSTITUTE FOR GLOBAL HEALTH   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c ROYAL PERTH HOSPITAL   (Australia)

^d WESTMEAD HOSPITAL   (Australia)

Author keywords

Cardiovascular diseases; Epidemiology; Meta analysis; Systematic review; Troponin

Indexed keywords

TROPONIN;

ARTICLE; ASYMPTOMATIC DISEASE; BIOASSAY; CARDIOVASCULAR EFFECT; CARDIOVASCULAR MORTALITY; DISEASE ASSOCIATION; HIGH RISK PATIENT; HUMAN; MORBIDITY; PATIENT ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PROTEIN DETERMINATION; RISK ASSESSMENT; SYSTEMATIC REVIEW; BLOOD; CARDIOVASCULAR DISEASE; FEMALE; MALE; META ANALYSIS; MORTALITY; RISK FACTOR;

CARDIOVASCULAR DISEASES; FEMALE; HUMANS; MALE; RISK FACTORS; TROPONIN;

EID: 84958106220     PISSN: 14439506     EISSN: 14442892     Source Type: Journal    
DOI: 10.1016/j.hlc.2015.09.001     Document Type: Article

References (48)

1. Australian absolute cardiovascular disease risk calculator. National Vascular Disease Prevention Alliance; Available from: . http://www.cvdcheck.org.au/.
2. New Zealand Cardiovascular Risk Charts. New Zealand Guidelines Group; 2009; Available from: . http://www.health.govt.nz/system/files/documents/publications/090311_cvd_poster_final.pdf.
3. EuroSCORE. EuroSCORE Study Group; 2011; Available from: . http://www.euroscore.org/calc.html.
4. Guidelines for the assessment of absolute cardiovascular disease risk. National Vascular Disease Prevention Alliance; 2009; Available from: . http://www.heartfoundation.org.au/SiteCollectionDocuments/guidelines-Absolute-risk.pdf.
5. Thygesen K., Alpert J.S., White H.D., Jaffe A.S., Apple F.S., Galvani M., et al. Universal definition of myocardial infarction. Circulation. 2007, 116(22):2634-2653.
6. Thygesen K., Mair J., Katus H., Plebani M., Venge P., Collinson P., et al. Recommendations for the use of cardiac troponin measurement in acute cardiac care. Eur Heart J. 2010, 31(18):2197-2204.
7. Khan N.A., Hemmelgarn B.R., Tonelli M., Thompson C.R., Levin A. Prognostic value of troponin T and I among asymptomatic patients with end-stage renal disease: A meta-analysis. Circulation 2005, 112(20):3088-3096.
8. Needham D.M., Shufelt K.A., Tomlinson G., Scholey J.W., Newton G.E. Troponin I and T levels in renal failure patients without acute coronary syndrome: a systematic review of the literature. Can J Cardiol. 2004, 20(12):1212-1218.
9. Latour-Perez J., Palencia-Herrejon E., Gordo-Vidal F., Sanchez-Artola Y.B. Prognostic value of troponin plasma levels in pulmonary thromboembolism: A systematic review and metal-analysis. Crit Care. 2005, 29(6):329-337.
10. Lim W., Qushmaq I., Devereaux P.J., Heels-Ansdell D., Lauzier F., Ismaila A.S., et al. Elevated cardiac troponin measurements in critically Ill patients. Arch Intern Med. 2006, 166(22):2446-2454.
11. Kerr G., Ray G., Wu O., Stott D.J., Langhorne P. Elevated troponin after stroke: A systematic review. Cerebrovasc Dis. 2009, 28(3):220-226.
12. Levy M., Heels-Ansdell D., Hiralal R., Bhandari M., Guyatt G., Yusuf S., et al. Prognostic value of troponin and creatine kinase muscle and brain isoenzyme measurement after noncardiac surgery: a systematic review and meta-analysis. Anesthesiology. 2011, 114(4):796-806.
13. Jiménez D UF, Otero R, Lobo JL, Monreal M, Martí D, Zamora J, et al., Troponin-based risk stratification of patients with acute nonmassive pulmonary embolism: systematic review and metaanalysis. Chest. 2009;136(4):974-82.
14. Croal B.L., Hillis G.S., Gibson P.H., Fazal M.T., El-Shafei H., Gibson G., et al. Relationship between postoperative cardiac troponin I levels and outcome of cardiac surgery. Circulation 2006, 114(14):1468-1475.
15. Stroup D.F., Berlin J.A., Morton S.C., Olkin I., Williamson G.D., Rennie D., et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000, 283(15):2008-2012.
16. Bodor GS SL, Voss EM, Smith S, Porterfield D, Apple FS. Cardiac troponin T composition in normal and regenerating human skeletal muscle. Clin Chem. 1997;43(3):476-84.
17. Saunders J.T., Nambi V., de Lemos J.A., Chambless L.E., Virani S.S., Boerwinkle E., et al. Cardiac troponin T measured by a highly sensitive assay predicts coronary heart disease, heart failure, and mortality in the Atherosclerosis Risk in Communities Study. Circulation. 2011, 123(13):1367-1376.
18. deFilippi C.R., de Lemos J.A., Christenson R.H., Gottdiener J.S., Kop W.J., Zhan M., et al. Association of serial measures of cardiac troponin T using a sensitive assay with incident heart failure and cardiovascular mortality in older adults. JAMA. 2010, 304(22):2494-2502.
19. de Lemos J.A., Drazner M.H., Omland T., Ayers C.R., Khera A., Rohatgi A., et al. Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population. JAMA. 2010, 304(22):2503-2512.
20. Everett B.M., Cook N.R., Magnone M.C., Bobadilla M., Kim E., Rifai N., et al. Sensitive cardiac troponin T assay and the risk of incident cardiovascular disease in women with and without diabetes mellitus: the Women's Health Study. Circulation. 2011, 123(24):2811-2818.
21. Eggers K.M., Al-Shakarchi J., Berglund L., Lindahl B., Siegbahn A., Wallentin L., et al. High-sensitive cardiac troponin T and its relations to cardiovascular risk factors, morbidity, and mortality in elderly men. Am Heart J. 2013, 166(3):541-548.
22. Xu R., Ye P., Luo L., Xiao W., Sheng L., Wu H., et al. Association between high-sensitivity cardiac troponin T and predicted cardiovascular risks in a community-based population. Int J Cardiol 2011, 149(2):253-256.
23. Otsuka T., Kawada T., Ibuki C., Seino Y. Association between high-sensitivity cardiac troponin T levels and the predicted cardiovascular risk in middle-aged men without overt cardiovascular disease. Am Heart J. 2010, 159(6):972-978.
24. Daniels L.B., Laughlin G.A., Clopton P., Maisel A.S., Barrett-Connor E. Minimally elevated cardiac troponin T and elevated N-terminal pro-B-type natriuretic peptide predict mortality in older adults: results from the Rancho Bernardo Study. J Am Coll Cardiol 2008, 52(6):450-459.
25. Setsuta K., Kitahara Y., Arae M., Ohbayashi T., Seino Y., Mizuno K. Elevated cardiac troponin T predicts adverse outcomes in hypertensive patients. Int Heart J. 2011, 52(3):164-169.
26. Wallace TW AS, Drazner MH, Das SR, Khera A, McGuire DK, Wians F, et al. Prevalence and determinants of troponin T elevation in the general population. Circulation. 2006;113(16):1958-65.
27. Sundström J IE, Berglund L, Zethelius B, Lind L, Venge P, Arnlöv J. Cardiac troponin-I and risk of heart failure: a community-based cohort study. Eur Heart J. 2009;30(7):773-81.
28. Zethelius B., Berglund L., Sundstrom J., Ingelsson E., Basu S., Larsso A., et al. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med 2008, 358(20):2107-2116.
29. Eggers K.M., Lind L., Ahlstrom H., Bjerner T., Ebeling Barbier C., Larsson A., et al. Prevalence and pathophysiological mechanisms of elevated cardiac troponin I levels in a population-based sample of elderly subjects. Eur Heart J. 2008, 29(18):2252-2258.
30. Blankenberg S., Zeller T., Saarela O., Havulinna A.S., Kee F., Tunstall-Pedoe H., et al. Contribution of 30 biomarkers to 10-year cardiovascular risk estimation in 2 population cohorts: the MONICA, risk, genetics, archiving, and monograph (MORGAM) biomarker project. Circulation 2010, 121(22):2388-2397.
31. Leistner D.M., Klotsche J., Pieper L., Stalla G.K., Lehnert H., Silber S., et al. Circulating troponin as measured by a sensitive assay for cardiovascular risk assessment in primary prevention. Clin Chem. 2012, 58(1):200-208.
32. McKie P.M., Heublein D.M., Scott C.G., Gantzer M.L., Mehta R.A., Rodeheffer R.J., et al. Defining high- sensitivity cardiac troponin concentrations in the community. Clin Chem. 2013, 59(7):1099-1107.
33. McKie P.M., AbouEzzeddine O., Scott C., Mehta R., Rodeheffer R., Redfield M.M., et al. High Sensitivity Troponin I and Amino-Terminal Pro- B-Type Natriuretic Peptide Predict Heart Failure and Mortality in the General Population. Clin Chem. 2014, 60(9):1225-1233.
34. Sinning C., Keller T., Zeller T., Ojeda F.M., Schluter M., Schnabel R., et al. Association of high-sensitivity assayed troponin I with cardiovascular phenotypes in the general population: the population- based Gutenberg health study. Clin Res Cardiol. 2014, 103(3):211-222.
35. Eggers K.M., Venge P., Lindahl B., Lind L. Cardiac troponin I levels measured with a high-sensitive assay increase over time and are strong predictors of mortality in an elderly population. J Am Coll Cardiol. 2013, 61(18):1906-1913.
36. Zeller T., Tunstall-Pedoe H., Saarela O., Ojeda F.M., Schnabel P.A., Tuovinen T., et al. High population prevalence of cardiac troponin I measured by a high-sensitivity assay and cardiovascular risk estimation: the MORGAM Biomarker Project Scottish Cohort. Eur Heart J. 2014, 35(5):271-281.
37. Wang T.J., Wollert K.C., Larson M.G., Coglianese E., McCabe E.L., Cheng S., et al. Prognostic utility of novel biomarkers of cardiovascular stress: the Framingham Heart Study. Circulation 2012, 126(13):1596-1604.
38. Zethelius B., Johnston N., Venge P. Troponin I as a predictor of coronary heart disease and mortality in 70-year-old men: a community-based cohort study. Circulation. 2006, 113(8):1071-1078.
39. Devereaux P.J., Chan M.T.V., Alonso-Coello P., Walsh M., Berwanger O., Villar J.C., et al. Association between postoperative troponin levels and 30-day mortality among patients undergoing noncardiac surgery. JAMA. 2012, 307(21):2295-2304.
40. Apple F.S. High-sensitivity cardiac troponin for screening large populations of healthy people: is there risk?. Clin Chem. 2011, 57(4):537-539.
41. Keller T., Munzel T., Blankenberg S. Making it more sensitive: the new era of troponin use. Circulation. 2011, 123(13):1361-1363.
42. de Lemos JA MD, deFilippi CR. Highly sensitive troponin assays and the cardiology community: a love/hate relationship? Clin Chem. 2011;57(6):826-9.
43. Wilson P.W., D'Agostino R.B., Levy D., Belanger A.M., Silbershatz H., Kannel W.B. Prediction of coronary heart disease using risk factor categories. Circulation. 1998, 97(18):1837-1847.
44. Di Angelantonio E., Chowdhury R., Sarwar N., Ray K.K., Gobin R., Saleheen D., et al. B-type natriuretic peptides and cardiovascular risk: systematic review and meta-analysis of 40 prospective studies. Circulation 2009, 120(22):2177-2187.
45. Parmacek M.S., Epstein J.A. Cardiomyocyte renewal. N Engl J Med. 2009, 361(1):86-88.
46. Olivetti G., Abbi R., Quaini F., Kajstura J., Cheng W., Nitahara J.A., et al. Apoptosis in the failing human heart. N Engl J Med. 1997, 336(16):1131-1141.
47. White H.D. Higher sensitivity troponin levels in the community: what do they mean and how will the diagnosis of myocardial infarction be made?. Am Heart J. 2010, 159(6):933-936.
48. Hickman P.E., Potter J.M., Aroney C., Koerbin G., Southcott E., Wu A.H.B., et al. Cardiac troponin may be released by ischemia alone, without necrosis. Clin Chim Acta. 2010, 411(5-6):318-323.